About NextCure, Inc.
https://www.nextcure.comNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.
CEO
Michael S. Richman MSBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-14 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Shares:978.57K
Value:$12.68M
BLACKROCK INC.
Shares:761.18K
Value:$9.86M
VHCP MANAGEMENT III, LLC
Shares:119.69K
Value:$1.55M
Summary
Showing Top 3 of 10
About NextCure, Inc.
https://www.nextcure.comNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.95M ▼ | $-8.62M ▲ | 0% | $-3.22 ▲ | $-8.09M ▲ |
| Q2-2025 | $0 | $27.29M ▲ | $-26.81M ▼ | 0% | $-11.29 ▼ | $-26.66M ▼ |
| Q1-2025 | $0 | $11.62M ▼ | $-10.98M ▲ | 0% | $-4.7 ▲ | $-10.97M ▲ |
| Q4-2024 | $0 | $12.46M ▼ | $-11.6M ▼ | 0% | $-4.97 ▼ | $-11.78M ▲ |
| Q3-2024 | $0 | $12.49M | $-11.54M | 0% | $-4.95 | $-11.79M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $29.11M ▼ | $39.61M ▼ | $15.97M ▼ | $23.65M ▼ |
| Q2-2025 | $35.31M ▼ | $47.69M ▼ | $16.04M ▲ | $31.65M ▼ |
| Q1-2025 | $55.86M ▼ | $67.14M ▼ | $11.28M ▼ | $55.85M ▼ |
| Q4-2024 | $68.62M ▼ | $80.86M ▼ | $15.39M ▲ | $65.47M ▼ |
| Q3-2024 | $75.31M | $90.34M | $14.75M | $75.59M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.62M ▲ | $-6.27M ▲ | $8.7M ▲ | $0 ▼ | $2.43M ▲ | $-6.27M ▲ |
| Q2-2025 | $-26.81M ▼ | $-22.71M ▼ | $3.76M ▼ | $2.02M ▲ | $-16.93M ▼ | $-22.71M ▼ |
| Q1-2025 | $-10.98M ▲ | $-12.99M ▼ | $7.09M ▲ | $0 ▼ | $-5.9M ▼ | $-12.99M ▼ |
| Q4-2024 | $-11.6M ▼ | $-6.97M ▲ | $6.96M ▼ | $36K ▲ | $25K ▼ | $-6.93M ▲ |
| Q3-2024 | $-11.54M | $-11.45M | $18.31M | $1K | $6.85M | $-11.62M |
CEO
Michael S. Richman MSBA
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-14 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Shares:978.57K
Value:$12.68M
BLACKROCK INC.
Shares:761.18K
Value:$9.86M
VHCP MANAGEMENT III, LLC
Shares:119.69K
Value:$1.55M
Summary
Showing Top 3 of 10